AKT1 and neoplasm: The tumor suppressor PTEN, a highly outcome-predictive marker, is altered in only 15-20% of early stage prostate cancers, yet is often functionally inactivated through a variety of other mechanisms that would be reflected in altered PI3K/AKT pathway activity [12].